• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    argenx Stock Gets A Lift From Positive Phase 3 Trial Results

    Simply Wall St·10/21/2026 05:37:19
    Listen to the news
    • argenx announced new data from its Phase 3 ALKIVIA trial of VYVGART Hytrulo in autoimmune myositis, where the study met its primary endpoint with a 15.4 point higher mean Total Improvement Score versus placebo at Week 52 and a safety profile consistent with prior efgartigimod studies.
    • The ALKIVIA results indicate that argenx is investing to extend VYVGART Hytrulo into difficult autoimmune muscle diseases. This development could reshape how its existing FcRn platform is used across multiple indications and influence long term portfolio concentration on efgartigimod based products.
    • The focus now turns to how argenx's broader investment narrative could evolve given Phase 3 results in autoimmune myositis using VYVGART Hytrulo.
    Spot 616 high quality undiscovered gems that, like argenx, are pushing hard in complex autoimmune and immunology indications before the wider market fully catches on.

    argenx Investment Narrative Recap

    To own argenx, you need to believe its FcRn platform and broader autoimmune portfolio can keep turning clinical wins into durable, diversified revenue while heavy R&D and SG&A spending stays manageable. The ALKIVIA success fits that story by reinforcing efgartigimod’s reach into difficult muscle diseases rather than changing it.

    Over the next year, the key swing factor is still how VYVGART and VYVGART Hytrulo perform across existing indications as competition and gross to net pressures build. The biggest risk remains product concentration on efgartigimod in an environment of rising rebates and pricing scrutiny, rather than this single myositis readout.

    The ALKIVIA data matters most when viewed next to argenx’s October decision to stop the UNITY Phase 3 trial in Sjögren's disease after an interim futility call. Together, they show the FcRn franchise is seeing both clear wins and hard stops across autoimmune settings, which is typical for a broad biologics program.

    For you as a shareholder, that Sjögren's setback keeps the spotlight on execution in indications where evidence is stronger and on diversification beyond efgartigimod, such as FB102 in celiac disease. Upcoming clinical disclosures and any label or reimbursement decisions around VYVGART Hytrulo still look like the more important near term operational catalysts.

    Analysts currently frame argenx's outlook around revenue rising to US$10.3b and earnings of US$3.1b by 2029. This implies forecast revenue growth of 24.6% per year and an earnings increase of US$1.4b from US$1.7b today.

    Discover how argenx's fair value indicates a 29% potential upside to its current price before the market closes that gap.

    ENXTBR:ARGX 1-Year Stock Price Chart
    ENXTBR:ARGX 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view puts regulatory and pricing pressure at the center of the argenx debate. You see that in the lowest analysts’ pre news assumptions. They still pencilled in revenue of about US$10.3b and earnings of US$3.7b by 2029, but only on a lower 19.1x P/E. That more cautious stance shows how far opinions can stretch, and why it helps to explore several narratives before deciding how this new ALKIVIA update might reshape the story.

    Explore 5 other argenx fair value estimates, including one that suggests it could be worth just €790.08.

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking for more investment ideas beyond argenx?

    Once you have a view on argenx, it can help to widen the lens and compare it with other businesses that fit different risk, quality, and income profiles using the Simply Wall St Screener.